- Tolerability and effectiveness of fulvestrant as first-line endocrine therapy in unselected patients with advanced breast cancer (ABC): Results of a multicenter, single arm, non-interventional studyZhao, Yannan; Geng, Cuizhi; Zhang, Hongwei; Cai, Li; Yao, Herui; Lin, Ying; Liu, Jianxia; Yang, Jin; Zhang, Jin; Wang, Xiaojia; Li, Yafen; Pang, Danmei; Sun, Tao; Wang, Xi; Ma, Jie; Zang, Aimin; Xu, Zhengyang; Wang, Yongsheng; Wang, Chuan; Hu, XichunAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Trastuzumab beyond progression in HER2‐positive metastatic breast cancerManwar, Al‐Naqqash; Waleed, Jasim Al‐Serarati; Tara, Farooq KareemBreast Journal, 2021, 27(3): 297-299.
- Primary results of a China bridging, phase II randomized study of initial endocrine therapy (ET) ± ribociclib (RIB) in pre- & postmenopausal Chinese women with HR+/HER2 ABCShao, Z.; Liu, Q.; Tong, Z.; Li, W.; Cai, L.; Bai, Y.; Amin, K.; Deshpande, P.; Bi, Y.; Xu, B.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
会议论文
PATTERNS OF CLINICAL MANAGEMENT AND RESOURCE UTILIZATION FOR POSTMENOPAUSAL HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE (HR+HER2-) ADVANCED BREAST CANCER (ABC) IN EUROPE
5阅读
